The NIH awarded Rules-Based Medicine (RBM) fast track funding of $849,000 to develop a diagnostic test for neonatal sepsis.
The company will collaborate with the University of New Mexico (UNM) in Albuquerque. UNM will provide samples from their neonatal intensive care ward.
RBM will perform all the testing and statistical analysis. The company will use its HumanMAP® platform to characterize and validate a pattern of biomarkers that can detect early signs of infection in newborns.
In a preliminary study, according to RBM, data indicated that a sensitive, specific diagnostic is possible where no predicate test exists today.